According to the latest research by InsightAce Analytic, the Global Chemotherapy-Induced Anemia Market is valued at US$ 2.4 Bn in 2023, and it is expected to reach US$ 3.9 Bn by 2031, with a CAGR of 6.5% during the forecast period of 2024-2031.
In chemotherapy-induced anemia, a patient has a decrease in hemoglobin while receiving chemotherapy. This disorder arises as a result of the fact that chemotherapy medications frequently target cells that divide quickly. The worldwide market for chemotherapy-induced anemia is anticipated to experience an increase due, in part, to the high incidence of both cancer and anemia among the elderly.
Download Free Sample Report Pages : https://www.insightaceanalytic.com/request-sample/2511
The invasion of bone marrow and the development of systemic inflammatory illness are driving up the demand for chemotherapy-induced anemia. Innovation and progress, technological developments, government incentives, and enhancements in pipeline items are also anticipated to be major drivers of market expansion over the projected time. The possibility of beneficial reimbursement policies is anticipated to create lucrative prospects for market growth in the coming years. However, the industry is expected to be hindered by regulatory hurdles related to approving and utilising chemotherapy-induced anemia treatment.
Also, the market is expected to slow down throughout the projected period due to specific manufacturing and pharmacological challenges associated with this chemotherapy-induced anemia therapy development. As a result of increased knowledge of chemotherapy-induced anemia and advancements in diagnostic techniques, chemotherapy patients with anemia can be better identified and treated, driving the market forward. These factors are expected to drive the growth of the chemotherapy-induced anemia market during the projected timeframe.
List of Prominent Players in the Chemotherapy-Induced Anemia Market:
Astellas Pharma Inc.
Blausen Medical
Dr. Reddy’s Laboratories Ltd.
Elsevier Inc.
F. Hoffmann-La Roche Ltd
FibroGen, Inc.
GlaxoSmithKline PLC
Healio
Johnson & Johnson
Karger AG
Novartis AG
Pfizer Inc.
Market Dynamics:
Drivers-:
The increasing rate of cancer cases worldwide is a key factor propelling the chemotherapy-induced anemia market. As the number of cancer patients undergoing chemotherapy rises, so does the number of people experiencing anemia as a typical side effect. There is a growing need for better anemia management due to the fact that chemotherapy has become harsh with the advancements in the field. In addition, there is a growing demand for supportive therapy due to increased awareness and better diagnostic methods that allow for better detection of chemotherapy-induced anemia. The market is being driven by the increasing size of the senior population, who are at a higher risk of developing cancer.
Challenges:
A major obstacle to the chemotherapy-induced anemia market is the regulatory climate, which requires lengthy clinical trials and strict permissions, which slows down the launch of novel medications. In addition, the market is also hindered by the expansion due to concerns over the safety profile of particular medicines. In addition, the availability of less expensive and more accessible alternatives to blood transfusions and other new anemia treatments can minimize the need for chemotherapy-induced anemia treatments.
Regional Trends:
The North American chemotherapy-induced anemia market is anticipated to register a major market share in revenue. It is projected to grow at a high CAGR in the near future because of the improved healthcare system and the proliferation of chemotherapeutic drugs. Also, the aging population is expected to experience lucrative growth in the next years as a result of the rising rates of cancer and anemia. Besides, Europe had a substantial share in the market because of the rapid urbanization, enhanced healthcare facilities, and abundant discretionary income, escalating rates of cancer as a result of unhealthy lifestyle choices, significant population suffering from anemia, and medical travel is on the rise, as a result of the dramatic rise in chemotherapy-induced anemia market in this region.
Curious about this latest version of the report? @ https://www.insightaceanalytic.com/enquiry-before-buying/2511
Recent Developments:
In May 2024, Xyphos Biosciences, Inc., a wholly-owned subsidiary of Astellas, and Poseida Therapeutics, Inc., a publicly traded company, announced that they have formed a research collaboration and license agreement to create new convertible car programs. This will be achieved by combining the cutting-edge cell therapy platforms of both companies.
·In March 2024, Elsevier, a world leader in providing information solutions and products for science, technology, and medicine, is pleased to announce the launch of a new open-access journal, CMI Communications, in collaboration with ESCMID, the leading European society for clinical microbiology and infectious diseases.
Segmentation of Chemotherapy-Induced Anemia Market-
Chemotherapy-Induced Anemia Market-By Type of Anemia
Mild Anemia
Moderate Anemia
Severe Anemia
Life-Threatening Anemia
Chemotherapy-Induced Anemia Market-By Treatment Type
RBC Transfusion
Erythropoiesis-stimulating agents (ESAs)
Iron Supplementation
Chemotherapy-Induced Anemia Market-By Drug Type
Epogen Injection
Procrit Injection
Androxy Oral
Aranesp Injection
Epoetin Alfa Injection
Others
Chemotherapy-Induced Anemia Market-By End-User
Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Others
Chemotherapy-Induced Anemia Market-By Region
North America-
The US
Canada
Mexico
Europe-
Germany
The UK
France
Italy
Spain
Rest of Europe
Asia-Pacific-
China
Japan
India
South Korea
South East Asia
Rest of Asia Pacific
Latin America-
Brazil
Argentina
Rest of Latin America
Middle East & Africa-
GCC Countries
South Africa
Rest of the Middle East and Africa
Media Contact
Company Name: InsightAce Analytic Pvt. Ltd
Contact Person: Diana D’Souza
Email: Send Email
Country: United States
Website: https://www.insightaceanalytic.com/
